Holen Sie sich die Stockscreener-App
4.23
18.82%
0.67
Handel nachbörslich:
4.27
0.04
+0.95%
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10TV
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Aug Sectors: Is X4 Pharmaceuticals Inc impacted by rising ratesPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now? - TradingView
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology - Investing.com
Amphastar (AMPH) CEO logs 10,850-share RSU tax withholding, retains large stake - Stock Titan
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Summary: Is X4 Pharmaceuticals Inc impacted by rising ratesTrade Analysis Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Guggenheim initiates X4 Pharmaceuticals stock with buy rating - Investing.com Australia
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - Yahoo Finance
Xenon Pharmaceuticals to Announce Topline Data from Phase 3 X-TOLE2 Study of Azetukalner for Focal Onset Seizures - Quiver Quantitative
Phase 3 seizure drug data Monday in Xenon focal onset study - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Can X4 Pharmaceuticals Inc lead its sector in growthJuly 2025 Reactions & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - The Manila Times
XFOR Technical Analysis & Stock Price Forecast - Intellectia AI
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
XFOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
Biotech X4 hires staff with stock options priced at $3.44 - Stock Titan
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
69,248 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Thornburg Investment Management Inc. - MarketBeat
EMA backs potential first WHIM treatment in EU after 60% infection drop - Stock Titan
Prescription Drug Costs - Britannica
XFOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
X4 Pharmaceuticals (XFOR) Price Target Increased by 16.67% to 9.52 - Nasdaq
ETF Watch: How much upside does X4 Pharmaceuticals Inc haveJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Final Week & Verified Chart Pattern Trade Signals - mfd.ru
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and SchizophreniaA New Chemical Entity Opening New Horizons in Psychiatric Innovation - Morningstar
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Tax-related stock sale by Rocket Pharma (RCKT) CEO Gaurav Shah - Stock Titan
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Artal Participations boosts Lexicon (NASDAQ: LXRX) stake with Series B preferred buy - Stock Titan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
AI Stocks: Will CADL stock go up in YEAR2025 Risk Factors & Precise Trade Entry Recommendations - baoquankhu1.vn
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Rocket Pharmaceuticals (RCKT) CEO sells shares to cover RSU taxes - Stock Titan
Can X4 Pharmaceuticals Inc. lead its sector in growthPortfolio Gains Summary & AI Based Trade Execution Alerts - mfd.ru
[SCHEDULE 13G/A] X4 Pharmaceuticals, Inc Amended Passive Investment Disclosure - Stock Titan
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Bain Capital Life Sciences reports 8.41% X4 (XFOR) stake including large warrant position - Stock Titan
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat
0.02%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):